BioVie (BIVI) Competitors $0.88 -0.07 (-7.65%) Closing price 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.19%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. IVVD, SLS, ACOG, ANL, RANI, CABA, VTGN, HLVX, ADAG, and EXOZShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Invivyd (IVVD), SELLAS Life Sciences Group (SLS), Alpha Cognition (ACOG), Adlai Nortye (ANL), Rani Therapeutics (RANI), Cabaletta Bio (CABA), Vistagen Therapeutics (VTGN), HilleVax (HLVX), Adagene (ADAG), and Exozymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Invivyd SELLAS Life Sciences Group Alpha Cognition Adlai Nortye Rani Therapeutics Cabaletta Bio Vistagen Therapeutics HilleVax Adagene Exozymes BioVie (NASDAQ:BIVI) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings. Which has higher earnings and valuation, BIVI or IVVD? BioVie has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$9.76-0.09Invivyd$25.38M2.60-$198.64M-$1.44-0.38 Does the MarketBeat Community believe in BIVI or IVVD? Invivyd received 6 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 85.71% of users gave Invivyd an outperform vote while only 66.67% of users gave BioVie an outperform vote. CompanyUnderperformOutperformBioVieOutperform Votes1866.67% Underperform Votes933.33% InvivydOutperform Votes2485.71% Underperform Votes414.29% Do analysts rate BIVI or IVVD? BioVie currently has a consensus target price of $3.00, suggesting a potential upside of 241.96%. Invivyd has a consensus target price of $7.89, suggesting a potential upside of 1,334.09%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Invivyd 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor BIVI or IVVD? In the previous week, Invivyd had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for BioVie. Invivyd's average media sentiment score of 0.62 beat BioVie's score of -0.11 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BIVI or IVVD? BioVie has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Is BIVI or IVVD more profitable? BioVie's return on equity of -134.07% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -134.07% -93.44% Invivyd N/A -155.33%-114.88% Do institutionals and insiders believe in BIVI or IVVD? 4.6% of BioVie shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 4.0% of BioVie shares are held by insiders. Comparatively, 17.9% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryInvivyd beats BioVie on 10 of the 16 factors compared between the two stocks. Remove Ads Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.19M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-0.096.9923.2518.07Price / SalesN/A198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book0.355.926.493.99Net Income-$32.12M$142.37M$3.21B$247.18M7 Day Performance-18.77%-9.32%-6.42%-6.42%1 Month Performance-25.65%-10.26%-0.68%-7.44%1 Year Performance76.63%-15.08%6.05%-4.31% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie2.3297 of 5 stars$0.88-7.7%$3.00+242.0%+81.3%$16.19MN/A-0.0910Short Interest ↓News CoverageIVVDInvivyd3.2739 of 5 stars$0.72-1.9%$7.89+989.4%-84.8%$86.60M$25.38M-0.37100SLSSELLAS Life Sciences Group0.0773 of 5 stars$1.23+2.5%N/A-7.6%$86.57M$1M-1.7810ACOGAlpha Cognition1.7986 of 5 stars$5.33-0.7%$20.00+275.2%N/A$85.39MN/A-2.08N/AEarnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpANLAdlai Nortye2.4346 of 5 stars$2.30+4.1%$9.00+291.3%-78.1%$84.87M$5M0.00127Positive NewsRANIRani Therapeutics2.6762 of 5 stars$1.47-5.2%$12.33+739.0%-55.7%$84.22MN/A-1.39110Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCABACabaletta Bio2.6908 of 5 stars$1.72-1.1%$22.71+1,220.6%-92.5%$84.07MN/A-0.8050Analyst ForecastAnalyst RevisionNews CoverageGap DownVTGNVistagen Therapeutics1.1133 of 5 stars$2.91+4.3%N/A-55.7%$83.99M$698,000.00-1.9740Gap DownHLVXHilleVax2.4866 of 5 stars$1.68flat$3.00+78.6%-90.4%$83.67MN/A-0.5420Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownADAGAdagene2.161 of 5 stars$1.77+5.0%$8.00+352.0%-45.3%$83.39M$815,746.000.00260Analyst ForecastGap DownHigh Trading VolumeEXOZExozymesN/A$13.11-11.5%N/AN/A$81.96MN/A0.0029News CoverageGap Up Remove Ads Related Companies and Tools Related Companies Invivyd Competitors SELLAS Life Sciences Group Competitors Alpha Cognition Competitors Adlai Nortye Competitors Rani Therapeutics Competitors Cabaletta Bio Competitors Vistagen Therapeutics Competitors HilleVax Competitors Adagene Competitors Exozymes Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIVI Stock Free BIVI Stock Alerts